| Compounds | Topics | Title | Date |
|---|---|---|---|
| THC,THC-COOH | metabolism in humans via trial (n=17) | Urinary Excretion Profile of 11-Nor-9-Carboxy-delta-9-Tetrahydrocannabinol (THCCOOH) Following Smoked and Vaporized Cannabis Administration in Infrequent Cannabis Users | May 2019 |
|
Ingestion Method: smoked/vaporized cannabis containing 0, 10, and 25 mg of THC Urinary concentrations of THCCOOH are dissimilar after administration of smoked and vaporized cannabis, with qualitatively higher concentrations observed after vaporization. Infrequent users of cannabis may excrete relatively low concentrations of THCCOOH following acute inhalation of smoked or vaporized cannabis. | |||
| THC,CBD | metabolism in humans via study (n=12) | d9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of Light Cannabis Smokers | Aug 2019 |
| THC and CBD time courses in the sera of light cannabis smokers were similar to those previously observed in oral fluid and blood. Serum THC/CBD concentration ratio not higher than the mean value of 0.9 might be a useful biomarker to identify use of light cannabis vs. that of illegal THC cannabis (where THC/CBDconcentration ratios are generally greater than 10) or vs. that of medical cannabis (where ratios are greater than 1). | |||
| cannabis | metabolism in humans via trial (n=23) | Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients | Jun 2019 |
| Our findings show that tetrahydrocannabinol (THC) breath concentrations peaked in 0.5 hours and reached baseline levels after 2 hours in all the patients. We found an inverse correlation between individuals' body mass index and their peak breath concentrations, and an inverse relationship between age and peak breath concentrations. | |||
| Sativex,CBD | drug potentiator,metabolism in humans via trial (n=9) | Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. | Jan 2011 |
| Decreases in mean 11-OH-THC Cmax and AUC0->10.5 hafter only high-dose Sativex might indicate that CBD does not interact with THC at lower doses (5 mg), but could alter THC metabolism at higher CBD doses (>=15 mg) | |||
| CBD | metabolism,safety via review | Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy | Mar 2016 |
| The present overview summarizes our current knowledge on the pharmacokinetics and metabolic fate of CBD in humans, reviews studies on the biological activity of CBD metabolites either in vitro or in vivo, and discusses relevant drug-drug interactions. To facilitate further research in the area, the reported syntheses of CBD metabolites are also catalogued. | |||
| cannabis | metabolism via review | Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination | Mar 2019 |
| This review comprehends the main secondary metabolites of Cannabis, approaching their therapeutic potential and applications, as well as their potential risks, in order to differentiate the consumption as recreational drugs. | |||
| JWH-018 | metabolism,safety in humans via experiment (n=17) | Neurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018: Responders Versus Nonresponders | Aug 2019 |
|
Ingestion Method: 2-6mg inhaled Serum concentrations of JWH-018 were significantly higher in the responders. Overall, JWH-018 increased heart rate within the first hour and significantly impaired critical tracking and memory performance. Responders to JWH-018 performed more poorly in tests measuring reaction time and showed increased levels of confusion, amnesia, dissociation, derealization, and depersonalization and increased drug liking after JWH-018. | |||
| cannabinoids | metabolism in mice | Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. | Mar 2011 |
| In n-3-deficient mice, presynaptic cannabinoid CB(1) receptors (CB(1)Rs) normally responding to endocannabinoids were uncoupled from their effector G(i/o) proteins. | |||
| PTL101 | metabolism,safety in humans | Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology. | Aug 2019 |
| PTL101 is a pharmaceutical-grade, user-friendly oral formulation that demonstrated safe and efficient delivery of CBD and therefore could be an attractive candidate for therapeutic indications. | |||
| ANA | metabolism via review | Brain activity of anandamide: a rewarding bliss? | Mar 2019 |
| We will also discuss how modulation of anandamide levels through inhibition of enzymatic metabolic pathways could provide a basis for developing new pharmaco-therapeutic tools for the treatment of substance use disorders. | |||
| THC,THC-OH,THC-COOH | metabolism in humans via experiment | Minimal Physiologically Based Pharmacokinetic Model of Intravenously and Orally Administered Delta-9-Tetrahydrocannabinol in Healthy Volunteers. | May 2019 |
|
Ingestion Method: oral 10, 25 and 50 mg THC, 0.1 mg/kg IV When administered via the IV or inhalation routes, induction or inhibition of CYP2C9 should be non-contributory as the elimination of THC is dependent only on liver blood flow. THC-OH is also a high extraction ratio drug, but its hepatic clearance is significantly impacted by the hepatic diffusional barrier that impedes its access to hepatic CYP2C9. THC-COOH is glucuronidated and renally cleared; subjects homozygous for CYP2C9*3 have reduced exposure to this metabolite as a result of the polymorphism reducing THC production, the hepatic diffusional barrier impeding egress from the hepatocyte, and increased renal clearance. | |||
| cannabis | metabolism in humans via experiment (n=118) | CNR1 and FAAH variation and affective states induced by marijuana smoking. | Jun 2019 |
| These preliminary findings suggest individual differences in mood states after using marijuana depend on genetic variation. Such information might be useful in understanding either motivation for use of marijuana and/or risk for associated behaviors. | |||